TG Therapeutics, Inc. (TGTX)

In our clinic, the transition to simpler administration protocols like the Phase III ENHANCE data supporting the 600-milligram single-infusion schedule has noticeably eased patient onboarding for relapsing multiple sclerosis. When evaluating Briumvi's clinical uptake against older anti-CD20 options, the combination of record patient starts and expanding physician comfort is hard to ignore. However, practitioners must keep a close eye on how the upcoming subcutaneous formulation—slated for late 2026 or early 2027 Phase 3 data—might further reshape our infusion-chair logistics and overall treatment paradigms.

On our desk, the immediate reaction to the Q2 EPS miss was a classic sell-the-news knee-jerk, but the retail and institutional narrative quickly refocused on the raise in full-year 2026 global revenue targets to $950 million. Watching the tape, it's clear that the CEO's $1 billion U.S. Briumvi target acts as a strong psychological floor for bulls. While valuation is no longer an absolute deep bargain after surging over 50% year-to-date, the top-line beat and strong international partnership contributions via Neuraxpharm keep our conviction intact.

From a quantitative risk perspective, TGTX presents a classic growth-versus-margin trade-off. While total global revenues grew over 70% year-over-year to $240.3 million in Q2, net income and EPS significantly lagged consensus estimates due to aggressive manufacturing investments. For risk managers, the core vulnerability lies in single-product concentration on Briumvi, making the pipeline optionality with assets like azer-cel and subcutaneous developments critical hedges against any unforeseen commercial deceleration or competitive headwinds in the multiple sclerosis market.